Journal Mobile Options
Table of Contents
Vol. 69, No. 2, 2005
Issue release date: September 2005
Oncology 2005;69:130–134
(DOI:10.1159/000087815)

A Phase II Trial of Gemcitabine, 5-Fluorouracil and Leucovorin in Advanced Esophageal Carcinoma

Morgan-Meadows S. · Mulkerin D. · Berlin J.D. · Kim K. · Bailey H. · Saphner T. · Jumonville A. · Hansen R. · Ahuja H. · McFarland T. · Thomas J.P.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The aim of this study was to evaluate the overall response rate, toxicity and overall survival in patients with locally advanced or metastatic esophageal cancer treated with gemcitabine, 5-fluorouracil (5-FU) and leucovorin. Patients and Methods: Patients with either adenocarcinoma or squamous cell carcinoma of the esophagus could enroll; however, patients could not have received prior chemotherapy for metastatic disease. Treatment cycles consisted of infusions of all three agents at days 1, 8 and 15, repeated every 28 days. Patients received gemcitabine 1,000, leucovorin 25 and 5-FU 600 mg/m2. Tumor assessment was performed every 2 cycles. Responses were assessed using the Eastern Cooperative Oncology Group solid tumor response criteria. Results: Thirty-five patients with metastatic or locally advanced esophageal cancer enrolled. One complete response and ten partial responses were observed for an overall response rate of 31.4%. An additional 11 patients had stable disease as their best response. The median survival was 9.8 months with a 1-year survival rate of 37.1%. Toxicity was predominately hematologic, with 58% of patients experiencing grade 3 or 4 neutropenia. Conclusion: The combination of gemcitabine, 5-FU and leucovorin had activity in advanced esophageal cancer. Patients tolerated the regimen well, with myelosuppression occurring most commonly. The combination merits further investigation as a treatment for esophageal cancer.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Jemel A, Tiwari RC, Murray T, et al: Cancer Statistics, 2004. CA Cancer J Clin 2004;54:8–29.
  2. Ezdinli EZ, Gelber R, Desai DV, et al: Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 1980;46:2149–2153.
  3. Davis S, Shanmugathasa M, Kessler W: Cis-dichlorodiammine platinum (II) in the treatment of esophageal carcinoma. Cancer Treat Rep 1980;64:709.
  4. Panettiere F, Leichman L, Tilchen EJ, Chen TT: Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study. Cancer Treat Rep 1984;68:1023–1024.
  5. Ilson DH, Saltz L, Enzinger P, et al: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999;17:3270–3275.
  6. Sandler AB, Kindler HL, Einhorn LH, et al: Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol 2000;11:1161–1164.
  7. Ajani J, Ilson D, Daugherty K, et al: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086–1091.
  8. Ren Q, Kao V, Grem JL: Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 1998;4:2811–2818.
  9. Berlin JD, Alberti DB, Arzoomanian RZ, et al: A phase I study of gemcitabine, 5-flourouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Invest New Drugs 1999;16:325–330.
  10. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
  11. Hayashi K, Ando N, Watanabe H, et al: Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407). Jpn J Clin Oncol 2001;31:419–423.
  12. Bleiberg H, Conroy T, Paillot B, et al: Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216–1220.
  13. Kroep JR, Pinedo HM, Giaccone G, Van Bochve A, Peters GJ, Van Groeningen CJ: Phase II study of cisplatin preceding gemcitabine in patients with advanced oesphageal cancer. Ann Oncol 2004;15:230–235.
  14. Urba SG, Chansky K, vanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL: Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs 2004;22:91–97.
  15. Kok TC, Van der Gaast A, Dees J, et al: Cisplatin and etoposide in oesophageal cancer: a phase II study. Br J Cancer 1996;74:980–984.
  16. Spiridonidis CH, Laufman LR, Jones JJ, et al: A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer 1996;77:2070–2077.
  17. Petrasch S, Welt A, Reinacher A, et al: Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998;78:511–514.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50